Itepekimab for chronic obstructive pulmonary disease therapy.

Area of Science:

• Pulmonology and immunology
• Inflammatory diseases

Background:

• Chronic obstructive pulmonary disease (COPD) exhibits diverse inflammation patterns, with Type 1 and Type 3 being most common.
• Type 2 inflammation, driven by interleukins (IL-4, IL-5, IL-13, IL-33), is less frequent but linked to increased disease severity, lung volume loss, and exacerbations.

Purpose of the Study:

• To review the scientific rationale for targeting IL-33 in COPD.
• To evaluate the therapeutic potential of itepekimab, an IL-33 blocking antibody, for COPD management.

Main Methods:

• Review of existing scientific literature on IL-33's role in COPD.
• Analysis of available clinical data for itepekimab in COPD patients.

Main Results:

• IL-33 is implicated in the pathogenesis and progression of COPD.
• Itepekimab demonstrates potential as a COPD therapy.

Conclusions:

• Itepekimab offers a promising therapeutic strategy for COPD.
• The drug is suitable for home administration with flexible dosing schedules (bi-weekly during exacerbations, monthly during stable states).